Original Article

Differences in National Antiretroviral Prescribing Patterns Between Black and White Patients with HIV/AIDS, 1996-2006

Authors: Christine U. Oramasionwu, PharmD, MS, PhD, Carolyn M. Brown, PhD, Kenneth A. Lawson, PhD, Laurajo Ryan, PharmD, MS, Jeff Skinner, MS, Christopher R. Frei, PharmD, MS

Abstract

Objectives: The benefit of improved health outcomes for blacks receiving highly active antiretroviral therapy (HAART) lags behind that of whites. This project therefore sought to determine whether the reason for this discrepancy in health outcomes could be attributed to disparities in use of antiretroviral therapy between black and white patients with HIV.


Materials and Methods: The 1996–2006 National Hospital Ambulatory Medical Care Surveys were used to identify hospital outpatient visits that documented antiretrovirals. Patients younger than 18 years, of nonblack or nonwhite race, and lacking documentation of antiretrovirals were excluded. A multivariable logistic regression model was constructed with race as the independent variable and use of HAART as the dependent variable.


Results: Approximately 3 million HIV/AIDS patient visits were evaluated. Blacks were less likely than whites to use HAART and protease inhibitors (odds ratio, 95% CI 0.81 [0.81–0.82] and 0.67 [0.67–0.68], respectively). More blacks than whites used non-nucleoside reverse transcriptase inhibitors (odds ratio, 95% CI 1.18 [1.17–1.18]). In 1996, the crude rates of HAART were relatively low for both black and white cohorts (5% vs 6%). The rise in HAART for blacks appeared to lag behind that of whites for several years, until 2002, when the proportion of blacks receiving HAART slightly exceeded the proportion of whites receiving HAART. In later years, the rates of HAART were similar for blacks and whites (81% vs 82% in 2006). Blacks appeared less likely than whites to use protease inhibitors and more likely than whites to use non-nucleoside reverse transcriptase inhibitors from 2000 to 2004.


Conclusions: Blacks experienced a lag in the use of antiretrovirals at the beginning of the study; this discrepancy dissipated in more recent years.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43: 27–34.
 
2. Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep 2002;117:233–251; discussion 231–232.
 
3. Oramasionwu CU, Skinner J, Ryan L, et al. Disparities in antiretroviral prescribing for blacks and whites in the United States. J Natl Med Assoc 2009;101:1140–1144.
 
4. Sambamoorthi U, Moynihan PJ, McSpiritt E, et al. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. Am J Public Health 2001;91:1474–1481.
 
5. Levine RS, Briggs NC, Kilbourne BS, et al.. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health 2007; 97: 1884–1892.
 
6. Blair JM, Fleming PL, Karon JM. Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990–1999. J Acquir Immune Defic Syndr 2002;31:339–347.
 
7. King WD, Minor P, Ramirez Kitchen C, et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrolees in 1998. J Epidemiol Community Health 2008;62:798–803.
 
8. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-Infected persons in care. J Infect Dis 2009;199:991–998.
 
9. Oramasionwu CU, Hunter JM, Skinner J, et al. Black race as a predictor of poor health outcomes among a national cohort of HIV/AIDS patients admitted to US hospitals: a cohort study. BMC Infect Dis 2009;9:127.
 
10. Oramasionwu CU, Brown CM, Lawson KA, et al. Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies. J Natl Med Assoc 2009;101:1221–1229.
 
11. Pletcher MJ, Kertesz SG, Kohn MA, et al. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008;299:70–78.
 
12. Pines JM, Russell Localio A, Hollander JE. Racial disparities in emergency department length of stay for admitted patients in the United States. Acad Emerg Med 2009;16:403–410.
 
13. Branner CM, Koyama T, Jensen GL. Racial and ethnic differences in pediatric obesity-prevention counseling: national prevalence of clinician practices. Obesity (Silver Spring) 2008;16:690–694.
 
14. Official Authorized Addenda. Human Immunodeficiency Virus Infection Codes and Official Guidelines for Coding and Reporting ICD-9-CM. Available at:http://www.cdc.gov/mmwr/preview/mmwrhtml/00032908.htm. Accessed March 29, 2009.
 
15. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society–USA. JAMA 1996;276:146–154.
 
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1–infected adults and adolescents. Department of Health and Human Services. 2011;1–161. Available at: http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed Feb 7, 2011.
 
17. Teshale E, Kamimoto L, Harris N, et al. Estimated number of HIV-Infected persons eligible for and receiving HIV antiretroviral therapy, 2003—United States. Conf Retrovir Opportunistic Infect 2005;12; abstract 167.
 
18. Lillie-Blanton M, Stone VE, Snow Jones A, et al. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health 2009;100:1493–1499.
 
19. Elford J, Ibrahim F, Bukutu C, et al. Uptake of antiretroviral treatment among people living with HIV in London: ethnicity, gender and sexual orientation. Sex Transm Infect 2008;84:176–178.
 
20. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96–103.
 
21. McNaghten AD, Hanson DL, Dworkin MS, et al. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003;32:499–505.
 
22. Holodniy M, Hornberger J, Rapoport D, et al. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1–infected US veterans (1992–2004). J Acquir Immune Defic Syndr 2007;44:20–29.
 
23. Moore RD, Stanton D, Gopalan R, et al. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763–768.
 
24. Reif S, Whetten K, Thielman N. Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. South Med J 2007;100:775–781.
 
25. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507–539.
 
26. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008;22: 385–393.
 
27. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008;22:F1–F9.
 
28. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1–17; quiz CE11-14.
 
29. Centers for Disease Control and Prevention. Diagnoses of HIV Infection and AIDS in the United States and dependent areas, 2008. Available at: http://www.cdc.gov/hiv/surveillance/resources/reports/2008report/index.htm. Accessed October 26, 2010.
 
30. Rubin MS, Colen CG, Link BG. Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. Am J Public Health 2010;100:1053–1059.
 
31. Levine RS, Rust GS, Pisu M, et al. Increased black-white disparities in mortality after the introduction of lifesaving innovations: a possible consequence of US federal laws. Am J Public Health 2010;100:2176–2184.
 
32. Centers for Disease Control and Prevention. HIV infection among young black men who have sex with men—Jackson, Mississippi, 2006–2008. MMWR Morb Mortal Wkly Rep 2009;58:77–81.
 
33. Late versus early testing of HIV—16 sites, United States, 2000–2003. MMWR Morb Mortal Wkly Rep 2003;52:581–586.
 
34. Estrada AL. Health disparities among African-American and Hispanic drug injectors—HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. AIDS 2005;19(3 suppl): S47–S52.
 
35. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14–18.
 
36. Newman LM, Berman SM. Epidemiology of STD disparities in African American communities. Sex Transm Dis 2008;35:S4–S12.